Aditxt Inc - ADTX STOCK NEWS

Aditxt, Inc. (NASDAQ: ADTX) has established a new subsidiary, Adimune, Inc., to advance its immunotherapeutic candidate, ADI™-100. A Clinical Trial Application (CTA) for human studies in psoriasis will be submitted, with trials expected to initiate in H2 2023. Dr. Joachim-Friedrich Kapp, an industry veteran, will lead Adimune as CEO. The company has reported positive toxicology results for ADI™-100, which aims to restore immune tolerance. This move aligns with Aditxt's strategy to commercialize innovative technologies and represents a significant milestone in their development pipeline.

Aditxt, Inc. (NASDAQ: ADTX) announced the commencement of GMP manufacturing for its drug candidate ADI™-100 under the Adimune™ program, aiming to start first-in-human trials in the second half of 2023, pending regulatory approvals. Targeting autoimmune diseases, it will initially focus on psoriasis. Previous toxicology studies confirm ADI™-100's safety. The global psoriasis treatment market is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, reflecting a strong potential for Adimune’s innovative approach that restores immune tolerance rather than suppressing it.

Aditxt, Inc. (NASDAQ: ADTX) announced the publication of a mathematical model for predicting the durability and decay rate of neutralizing antibodies (NAb) to SARS-CoV-2 in the Journal of Theoretical Biology. Developed with Dr. Lisette de Pillis, the model aims to evaluate immune responses to COVID-19 vaccination. It provides insights that could help tailor immunization protocols and aid in vaccine development. Potential applications include identifying vulnerable populations, accelerating clinical trials, and optimizing booster timing.

Aditxt, Inc. (NASDAQ: ADTX) has been featured by FedEx in a video presentation highlighting its AditxtScore™ technology, which helps monitor immune responses to COVID-19. The company collaborates with FedEx to ensure timely delivery of blood samples critical for processing and generating personalized immune profiles using proprietary technologies. Aditxt aims to enhance understanding of immune status, assisting healthcare professionals in making informed vaccination decisions.

Aditxt, Inc. (NASDAQ: ADTX) has confirmed compliance with Nasdaq's minimum bid price and stockholders' equity requirements. This compliance follows a recent reverse stock split and a successful $20 million public offering. CEO Amro Albanna highlighted that these steps are crucial for the company's ongoing programs, which include AditxtScore™, Adimune™, and Adivir™, aimed at monitoring and modulating the immune system. Aditxt continues to develop technologies to personalize immune profiles and address organ rejection, autoimmune diseases, and allergies.

Aditxt, Inc. (Nasdaq: ADTX) has completed a reverse stock split and closed a $20 million public offering, crucial for advancing its key programs: AditxtScore™, Adimune™, and Adivir™. The reverse split positions the company for compliance with Nasdaq requirements, with 3,708,647 shares outstanding. AditxtScore™ is seeing revenue growth, while Adimune™ is preparing for clinical trials and Adivir™ holds potential revenue from a partnership with Cellvera. This development could lead to improved financial health and product advancement in immune system technologies in 2023.

Aditxt, Inc. (Nasdaq: ADTX) has successfully closed a public offering, selling 3,333,333 shares of common stock and warrants at a combined price of $6.00 each. The gross proceeds from the offering total approximately $20.0 million, which will be utilized for operating expenses and working capital. The warrants, with an exercise price of $6.00, are immediately exercisable and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.

Aditxt, Inc. (Nasdaq: ADTX) announced a public offering of 3,333,333 shares of common stock and associated warrants at $6.00 per unit, aiming to raise approximately $20 million. The warrants, with an exercise price of $6.00, are exercisable immediately and expire in five years. Proceeds will fund general corporate expenses, including R&D and potential acquisitions, although no current commitments are in place. Closing of the offering is expected around September 20, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.

Aditxt, Inc. (Nasdaq: ADTX) announced a 1-for-50 reverse stock split effective September 13, 2022. The split aims to comply with Nasdaq's $1.00 per share minimum bid price requirement. Post-split, approximately 1,156,674 shares will be outstanding with the CUSIP number 007025505. The reverse split was approved by stockholders during a special meeting on September 7, 2022. Trading on a post-split basis will begin on September 14, 2022. Aditxt focuses on immune system monitoring and modulation technologies.